AngioDynamics, Inc. (NASDAQ:ANGO)’s share price hit a new 52-week high during mid-day trading on Wednesday . The company traded as high as $23.25 and last traded at $23.11, with a volume of 3668 shares. The stock had previously closed at $23.09.
A number of equities analysts have recently issued reports on ANGO shares. TheStreet upgraded shares of AngioDynamics from a “c” rating to a “b-” rating in a research report on Monday, April 16th. ValuEngine upgraded shares of AngioDynamics from a “hold” rating to a “buy” rating in a research report on Friday, April 6th. BidaskClub upgraded shares of AngioDynamics from a “hold” rating to a “buy” rating in a research report on Friday, March 30th. Zacks Investment Research lowered shares of AngioDynamics from a “buy” rating to a “hold” rating in a research report on Tuesday, June 5th. Finally, Canaccord Genuity upped their target price on shares of AngioDynamics from $16.50 to $17.00 and gave the stock a “hold” rating in a research report on Monday, April 2nd. Five investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company. AngioDynamics currently has a consensus rating of “Buy” and an average target price of $17.87.
The firm has a market cap of $846.50 million, a price-to-earnings ratio of 31.36, a P/E/G ratio of 1.66 and a beta of 1.01. The company has a current ratio of 2.88, a quick ratio of 1.84 and a debt-to-equity ratio of 0.16.
AngioDynamics (NASDAQ:ANGO) last announced its quarterly earnings data on Thursday, March 29th. The medical instruments supplier reported $0.25 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.20 by $0.05. AngioDynamics had a net margin of 0.97% and a return on equity of 5.11%. The business had revenue of $83.85 million for the quarter, compared to analyst estimates of $86.13 million. equities research analysts forecast that AngioDynamics, Inc. will post 0.74 EPS for the current fiscal year.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Aperio Group LLC acquired a new position in AngioDynamics in the first quarter valued at approximately $192,000. Teacher Retirement System of Texas acquired a new position in AngioDynamics in the fourth quarter valued at approximately $201,000. Port Capital LLC acquired a new position in AngioDynamics in the first quarter valued at approximately $213,000. Fisher Asset Management LLC acquired a new position in AngioDynamics in the first quarter valued at approximately $215,000. Finally, Element Capital Management LLC acquired a new position in AngioDynamics in the first quarter valued at approximately $217,000. Institutional investors and hedge funds own 98.38% of the company’s stock.
AngioDynamics, Inc designs, manufactures, and sells various medical, surgical, and diagnostic devices for the treatment of peripheral vascular disease, vascular access, and for use in oncology and surgical settings in the United States and internationally. The company provides manifolds, contrast management systems, closed fluid systems, guidewires, disposable transducers, and interventional accessories that help clinicians in the diagnosis and treatment of cardiovascular and peripheral vascular diseases; VenaCure EVLT laser system products to treat superficial venous diseases; Asclera drug for treating uncomplicated spider and reticular veins of the lower extremities; and Sotradecol drugs for treating small uncomplicated varicose veins of the lower extremities.
Receive News & Ratings for AngioDynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics and related companies with MarketBeat.com's FREE daily email newsletter.